Modes of resistance to anti-angiogenic therapy

Cited by (1,005)

Items 601–700 of 1,005

1. Drug resistance in cancer: molecular evolution and compensatory proliferation
   Ran Friedman · 2016 · Oncotarget
2. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study
   Evangelos C. Briasoulis, Gerasimos Aravantinos, George Kouvatseas, Periklis Pappas, Eirini Biziota, Ioannis Sainis, Thomas Makatsoris, Ioannis I. Varthalitis, Ioannis Xanthakis, Antonios Vassias et al. · 2013 · BMC Cancer
3. Near-infrared light-activated IR780-loaded liposomes for anti-tumor angiogenesis and Photothermal therapy
   Xue Yang, Huipeng Li, Chenggen Qian, Yuxin Guo, Chenzi Li, Fang Gao, Ying Nan Yang, Kaikai Wang, David Oupický, Minjie Sun · 2018 · Nanomedicine Nanotechnology Biology and Medicine
4. Tumors vs. Chronic Wounds: An Immune Cell's Perspective
   Yichao Hua, Gabriele Bergers · 2019 · Frontiers in Immunology
5. Targeted therapy of thyroid cancer
   Steven I. Sherman · 2010 · Biochemical Pharmacology
6. Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts
   Krishan Kumar, Simon Wigfield, Harriet E. Gee, Cecilia M. Devlin, Dean C. Singleton, Ji‐Liang Li, Francesca Meteora Buffa, Melanie Huffman, Anthony L. Sinn, Jayne M. Silver et al. · 2013 · Journal of Molecular Medicine
7. Selective Killing of Tumor Neovasculature Paradoxically Improves Chemotherapy Delivery to Tumors
   Freddy E. Escorcia, Erik Henke, Michael R. McDevitt, Carlos H. Villa, Peter M Smith-Jones, Ronald G. Blasberg, Robert Benezra, David A. Scheinberg · 2010 · Cancer Research
8. Metastasis regulation by PPARD expression in cancer cells
   Xiangsheng Zuo, Weiguo Xu, Min Xu, Rui Tian, Micheline J. Moussalli, Fei Mao, Xiaofeng Zheng, Jing Wang, Jeffrey S. Morris, Mihai Gagea et al. · 2017 · JCI Insight
9. EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance
   Cornelia Depner, H. zum Buttel, Nuray Böğürcü, Ángel M. Cuesta, María R. Aburto, Sascha Seidel, Fabian Finkelmeier, Franziska Foss, J. Hofmann, Kerstin Kaulich et al. · 2016 · Nature Communications
10. Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer
    James R. W. Conway, Sean C. Warren, David Herrmann, Kendelle Joan Murphy, Aurélie Cazet, Claire Vennin, Robert F. Shearer, Monica J Killen, Astrid Magenau, Pauline Mélénec et al. · 2018 · Cell Reports
11. Second-line lenvatinib in patients with recurrent endometrial cancer
    Ignace B. Vergote, Matthew A. Powell, Michael G. Teneriello, David Scott Miller, Agustin A. García, Olga N. Mikheeva, Mariusz Bidziński, Cristina Ligia Cebotaru, Corina E. Dutcus, Min Ren et al. · 2020 · Gynecologic Oncology
12. Dual role of endothelial Myct1 in tumor angiogenesis and tumor immunity
    Ashraf Ul Kabir, Madhav Subramanian, Dong Hun Lee, Xiaoli Wang, Karen Krchma, Jun Wu, Teri Naismith, Carmen M. Halabi, Ju Young Kim, Fadi E. Pulous et al. · 2021 · Science Translational Medicine
13. Effect of Rifampicin on the Pharmacokinetics of Lenvatinib in Healthy Adults
    Robert C. Shumaker, Jagadeesh Aluri, Jean Fan, Gresel Martinez, Gary A. Thompson, Min Ren · 2014 · Clinical Drug Investigation
14. Pericytes: A Double-Edged Sword in Cancer Therapy
    Mao-Bin Meng, Nicholas George Zaorsky, Lei Deng, Huan-Huan Wang, Chao Jiang, Lu‐Jun Zhao, Zhiyong Yuan, Ping Wang · 2014 · Future Oncology
15. Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells
    Gottfried E. Konecny, Teodora R. Kolarova, Neil A. O’Brien, Boris J. N. Winterhoff, Guorong Yang, Jingwei Qi, Zhengdong Qi, Natarajan Venkatesan, Raul Ayala, Tong Luo et al. · 2013 · Molecular Cancer Therapeutics
16. Molecular Mechanisms and Bioavailability of Polyphenols in Prostate Cancer
    Teodora Costea, Péter Nagy, Constanţa Ganea, János Szöllõsi, Maria‐Magdalena Mocanu · 2019 · International Journal of Molecular Sciences
17. Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment
    Xianbo Wu, Jie Wang, Qi Liang, Rongsheng Tong, Jianli Huang, Xinwei Yang, Yihua Xu, Wenjing Wang, Minghan Sun, Jianyou Shi · 2022 · Biomedicine & Pharmacotherapy
18. Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab
    Yingmiao Liu, Mark D. Starr, Anuradha Bulusu, Herbert Pang, Nan Soon Wong, Wanda Honeycutt, Anthony Amara, Herbert I. Hurwitz, Andrew B. Nixon · 2013 · Cancer Medicine
19. Vascular targeting of adipose tissue as an anti-obesity approach
    Alexes C. Daquinag, Yan Zhang, Mikhail G. Kolonin · 2011 · Trends in Pharmacological Sciences
20. Protein kinase D2 is a crucial regulator of tumour cell–endothelial cell communication in gastrointestinal tumours
    Ninel Azoitei, Ganesh Varma Pusapati, Alexander Kleger, Peter Möller, R. Küfer, Felicitas Genze, Martin Wagner, Johan Van Lint, Peter Carmeliet, Guido Adler et al. · 2010 · Gut
21. Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab
    Atsushi Mitsuhashi, Hisatsugu Goto, Atsuro Saijo, Van The Trung, Yoshinori Aono, Hirokazu Ogino, Takuya Kuramoto, Sho Tabata, Hisanori Uehara, Keisuke Izumi et al. · 2015 · Nature Communications
22. Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patient
    Eva Dazert, Marco Colombi, Tuyana Boldanova, Suzette Moes, David Adametz, Luca Quagliata, Volker Röth, Luigi Terracciano, Markus Hermann Heim, Paul Jenoe et al. · 2016 · Proceedings of the National Academy of Sciences
23. Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer
    Anubha Gupta, Barbara Jarząb, Jaume Capdevila, Robert Shumaker, Ziad Hussein · 2016 · British Journal of Clinical Pharmacology
24. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma
    Robert John Motzer, Thomas E. Hutson, Gary R. Hudes, Robert A. Figlin, Jean-François Martini, Patricia A. English, Xin Huang, Olga Valota, James Andrew Williams · 2014 · Cancer Chemotherapy and Pharmacology
25. A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
    Derek J. Jonker, Lee S. Rosen, Michael B. Sawyer, Filippo de Braud, George Wilding, Christopher J. Sweeney, Gordon C. Jayson, Grant A. McArthur, Gordon J.S. Rustin, Glenwood D. Goss et al. · 2010 · Annals of Oncology
26. High IDO ‐1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma
    Andreas Seeber, Gerald Klinglmair, Josef Fritz, Fabian Steinkohl, Kai‐Christian Zimmer, Friedrich Aigner, Wolfgang Horninger, Günther A. Gastl, Bettina Gudrun Zelger, Andrea Brunner et al. · 2018 · Cancer Science
27. Immunomodulation of Tumor Vessels: It Takes Two to Tango
    Anna Johansson, Bo He, Ruth Ganß · 2018 · Trends in Immunology
28. Regulatory mechanisms and therapeutic targeting of vasculogenic mimicry in hepatocellular carcinoma
    Ning Zheng, Shaoqin Zhang, Wenda Wu, Nan Zhang, Jichuang Wang · 2021 · Pharmacological Research
29. An Anti-Vascular Endothelial Growth Factor Receptor 2/Fetal Liver Kinase-1 Listeria monocytogenes Anti-Angiogenesis Cancer Vaccine for the Treatment of Primary and Metastatic Her-2/neu+ Breast Tumors in a Mouse Model
    Matthew M. Seavey, Paulo Maciag, Nada Al-Rawi, Duane A. Sewell, Yvonne Y.W. Paterson · 2009 · The Journal of Immunology
30. Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma
    Peter Olson, Gerald C. Chu, Samuel R. Perry, Olivier Nolan-Stevaux, Douglas Hanahan · 2011 · Proceedings of the National Academy of Sciences
31. Targeting the VEGF signaling pathway in cancer therapy
    Maximilian J. Waldner, Markus Friedrich Neurath · 2012 · Expert Opinion on Therapeutic Targets
32. Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme
    Aida Muhic, Hans Skovgaard Poulsen, Morten Mau‐Sørensen, Kirsten Grunnet, Ulrik Lassen · 2012 · Journal of Neuro-Oncology
33. A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinoma
    Gyanchandani, Rekha, Ortega Alves, Marcus V., Myers, Jeffrey N., Kim, Seungwon · 2013 · Molecular Cancer Research
34. Molecular Therapeutic Targets for Glioma Angiogenesis
    Shingo Takano, Toshiharu Yamashita, Osamu Ohneda · 2010 · Journal of Oncology
35. Ca2+ Influx through Reverse Mode Na+/Ca2+ Exchange Is Critical for Vascular Endothelial Growth Factor-mediated Extracellular Signal-regulated Kinase (ERK) 1/2 Activation and Angiogenic Functions of Human Endothelial Cells
    Petros Andrikopoulos, Akemichi Baba, Toshio Matsuda, Mustafa B.A. Djamgoz, Muhammad Yaqoob, Suzanne A. Eccles · 2011 · Journal of Biological Chemistry
36. The VEGF/Rho GTPase signalling pathway: A promising target for anti-angiogenic/anti-invasion therapy
    Roy van der Meel, Marc H. Symons, Robert Kudernatsch, Robbert J. Kok, Raymond Michel Schiffelers, Gert Storm, William M. Gallagher, Annette T. Byrne · 2011 · Drug Discovery Today
37. NCI–RTOG Translational Program Strategic Guidelines for the Early-Stage Development of Radiosensitizers
    Yaacov Richard Lawrence, Bhadrasain Vikram, James J. Dignam, Arnab Chakravarti, Mitchell X. Machtay, Boris Freidlin, Naoko Takebe, Walter John Curran, Søren Møller Bentzen, Paul G Okunieff et al. · 2012 · JNCI Journal of the National Cancer Institute
38. The non-canonical NOTCH ligand DLK1 exhibits a novel vascular role as a strong inhibitor of angiogenesis
    Patricia Q. Rodriguez, María Ángeles Higueras, Álvaro González-Rajal, Arántzazu Alfranca, Marta Fierro‐Fernández, Rosa Ana García-Fernández, María José Ruiz‐Hidalgo, Marı́a Monsalve, Fernando Rodríguez‐Pascual, Juan Miguel Redondo et al. · 2011 · Cardiovascular Research
39. Classical VEGF, Notch and Ang signalling in cancer angiogenesis, alternative approaches and future directions
    Nunzia Caporarello, Gabriella Lupo, Melania Olivieri, Martina Cristaldi, Maria Teresa Cambria, Mario Salmeri, Carmelina Daniela Anfuso · 2017 · Molecular Medicine Reports
40. Claudin-5 Redistribution Induced by Inflammation Leads to Anti-VEGF–Resistant Diabetic Macular Edema
    Mitsuru Arima, Shintaro Nakao, Muneo Yamaguchi, Hao Feng, Yuya Fujii, Kensuke Shibata, Iori Wada, Yoshihiro Kaizu, Hamid Ahmadieh, Tatsuro Ishibashi et al. · 2020 · Diabetes
41. Anti‐VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models
    Mallika Singh, Suzana S. Couto, William F. Forrest, Anthony Lima, Jason H. Cheng, Rafael Molina, Jason E. Long, Patricia Hamilton, Angela McNutt, Ian M. Kasman et al. · 2012 · The Journal of Pathology
42. Endothelial progenitor cells support tumour growth and metastatisation: implications for the resistance to anti-angiogenic therapy
    Francesco Domenico Moccia, Estella Zuccolo, Valentina Poletto, Mariapia Cinelli, Elisa Bonetti, Germano Guerra, Vittorio Rosti · 2015 · Tumor Biology
43. Dual-Drug Backboned Polyprodrug with a Predefined Drug Combination for Synergistic Chemotherapy
    Fangzhou Yu, Yalan Tu, Shiwei Luo, Xuan Xiao, Yao Wang, Maolin Jiang, Xinqing Jiang, Ruimeng Yang, Youyong Yuan · 2021 · Nano Letters
44. Targeting macrophages: a novel treatment strategy in solid tumors
    Mengmeng Liu, Lina Liu, Yongping Song, Wei Li, Linping Xu · 2022 · Journal of Translational Medicine
45. Milestones in tumor vascularization and its therapeutic targeting
    Michele De Palma, Douglas Hanahan · 2024 · Nature Cancer
46. Development of a Resistance-like Phenotype to Sorafenib by Human Hepatocellular Carcinoma Cells Is Reversible and Can Be Delayed by Metronomic UFT Chemotherapy
    Terence Tang, Shan Man, Ping Xu, Giulio Francia, Kae Hashimoto, Urban Emmenegger, Robert S. Kerbel · 2010 · Neoplasia
47. Sunitinib induces cellular senescence via p53/ D ec1 activation in renal cell carcinoma cells
    Yu Zhu, Le Xu, Jianping Zhang, Xiaoyi Hu, Yujun Liu, Hankun Yin, Tao Lv, Heng Zhang, Li Liu, Huimin An et al. · 2013 · Cancer Science
48. Irradiation-induced angiogenesis is associated with an MMP-9-miR-494-syndecan-1 regulatory loop in medulloblastoma cells
    Swapna Asuthkar, Kiran Kumar Velpula, Arun Kumar Nalla, Venkateswara Rao Gogineni, Christopher S. Gondi, Jia‐Sheng Rao · 2013 · Oncogene
49. Glycolytic Phenotype and AMP Kinase Modify the Pathologic Response of Tumor Xenografts to VEGF Neutralization
    Giorgia Nardo, Elena Favaro, Matteo Curtarello, Lidia Moserle, Elisabetta Zulato, Luca Persano, Elisabetta Maria Cristina Rossi, Giovanni Esposito, Marika Crescenzi, Oriol Casanovas et al. · 2011 · Cancer Research
50. Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer
    Madelon Paauwe, Renier C. Heijkants, C.H. Oudt, Gabi W. van Pelt, Chao Cui, Charles P. Theuer, James C.H. Hardwick, Cornelis F.M. Sier, Lukas J.A.C. Hawinkels · 2016 · Oncogene
51. EGFL6 Regulates the Asymmetric Division, Maintenance, and Metastasis of ALDH+ Ovarian Cancer Cells
    Shoumei Bai, Patrick Ingram, Yu‐Chih Chen, Ning Deng, Alexander T. Pearson, Yashar S. Niknafs, Patrick O’Hayer, Yun Wang, Zhong‐Yin Zhang, Elisa Boscolo et al. · 2016 · Cancer Research
52. Wnt5a and its signaling pathway in angiogenesis
    Yaning Shi, Neng Zhu, Chan Liu, Hongtao Wu, Yu Gui, Duan‐Fang Liao, Qin Li · 2017 · Clinica Chimica Acta
53. Selective eradication of tumor vascular pericytes by peptide-conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis
    Ying‐Yun Guan, Xin Luan, Jianrong Xu, Yarong Liu, Qin Lu, Chao Wang, Hai-Jun Liu, Yunge Gao, Hongzhuan Chen, Chao Fang · 2014 · Biomaterials
54. A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer
    George Fountzilas, Anna Fragkoulidi, Anna Kalogera‐Fountzila, Martha Nikolaidou, Mattheos Bobos, Julien Caldéraro, Felipe Da Matta Andreiuolo, Μάριος Μαρσέλος · 2009 · Cancer Chemotherapy and Pharmacology
55. MR-based hypoxia measures in human glioma
    Vivien Tóth, Annette Förschler, Nuria M. Hirsch, Jürgen den Hollander, Hendrik Kooijman, Jens Gempt, Florian A. Ringel, Jürgen Schlegel, Claus Zimmer, Christine Preibisch · 2013 · Journal of Neuro-Oncology
56. The lymphatic system and pancreatic cancer
    Darci M. Fink, Maria M. Steele, Michael Anthony Hollingsworth · 2015 · Cancer Letters
57. Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities
    Venessa T. Chin, Adnan M. Nagrial, Angela S. Y. Chou, Andrew Victor Biankin, Anthony James Gill, Paul Timpson, Marina Pajic · 2015 · Expert Reviews in Molecular Medicine
58. Magnetically Guided Self-Assembled Protein Micelles for Enhanced Delivery of Dasatinib to Human Triple-Negative Breast Cancer Cells
    Sally A. Sabra, Salah Ahmed Sheweita, Medhat Haroun, Doaa Ragab, Maha El Demellawy, Ying Xia, David B. Goodale, Alison L. Allan, Ahmed O. Elzoghby, Sohrab Rohani · 2018 · Journal of Pharmaceutical Sciences
59. VEGF-Targeted Therapy Stably Modulates the Glycolytic Phenotype of Tumor Cells
    Matteo Curtarello, Elisabetta Zulato, Giorgia Nardo, Silvia Valtorta, Giulia Guzzo, Elisabetta Maria Cristina Rossi, Giovanni Esposito, Aichi Msaki, Anna Pastò, Andrea Rasola et al. · 2014 · Cancer Research
60. Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors
    Giulia Taraboletti, Marco Rusnati, Laura Ragona, Giorgio Colombo · 2010 · Oncotarget
61. Advances in non-surgical management of primary liver cancer
    Xiao Chen · 2014 · World Journal of Gastroenterology
62. AngioMatrix, a signature of the tumor angiogenic switch-specific matrisome, correlates with poor prognosis for glioma and colorectal cancer patients
    Benoît Langlois, Falk Saupe, Tristan Rupp, Christiane Arnold, Michaël van der Heyden, Gertraud Orend, Thomas Hussenet · 2014 · Oncotarget
63. An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer
    Michael S. Gordon, Francisco Robert, Daniela Elena Matei, David S. Mendelson, Jonathan Wade Goldman, Elena Gabriela Chiorean, Robert Matthew Strother, Ben K. Seon, William Douglas Figg, Cody J. Peer et al. · 2014 · Clinical Cancer Research
64. Autophagy, a double-edged sword in anti-angiogenesis therapy
    Jiatao Liu, Lulu Fan, Hua Wang, Guoping Sun · 2015 · Medical Oncology
65. Galectin-3 Inhibition by a Small-Molecule Inhibitor Reduces Both Pathological Corneal Neovascularization and Fibrosis
    Wei‐Sheng Chen, Zhiyi Cao, Hakon Leffler, Ulf J. Nilsson, Noorjahan Panjwani · 2017 · Investigative Ophthalmology & Visual Science
66. Glioblastoma stem cells exploit the αvβ8 integrin-TGFβ1 signaling axis to drive tumor initiation and progression
    Paola A. Guerrero, Jeremy H. Tchaicha, Zhongjian Chen, John E. Morales, N McCarty, Q Wang, Erik P. Sulman, Gregory N. Fuller, Frederick F. Lang, Ganesh Rao et al. · 2017 · Oncogene
67. Glioblastoma: To Target the Tumor Cell or the Microenvironment?
    Steven De Vleeschouwer, Gabriele Bergers · 2017 · Codon Publications eBooks
68. The role of tumor microenvironment in resistance to anti-angiogenic therapy
    Shaolin Ma, Sunila Pradeep, Wei Hu, Dikai Zhang, Robert Louis Coleman, Anil K. Sood · 2018 · F1000Research
69. The role of tumor angiogenesis as a therapeutic target in colorectal cancer
    Francesca Battaglin, Alberto Puccini, Rossana Intini, Marta Schirripa, Alessandra Ferro, Francesca Bergamo, Sara Lonardi, Vittorina Zagonel, Heinz‐Josef Lenz, Fotios Loupakis · 2018 · Expert Review of Anticancer Therapy
70. Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience
    Víctor Moreno, Bristi Basu, L. Rhoda Molife, Stan B. Kaye · 2012 · Clinical Cancer Research
71. Selectively Suppressing Tumor Angiogenesis for Targeted Breast Cancer Therapy by Genetically Engineered Phage
    Yan Li, Xuewei Qu, Binrui Cao, Tao Yang, Qing Bao, Yue Hui, Liwei Zhang, Genwei Zhang, Lin Wang, Penghe Qiu et al. · 2020 · Advanced Materials
72. Tumors That Acquire Resistance to Low-Dose Metronomic Cyclophosphamide Retain Sensitivity to Maximum Tolerated Dose Cyclophosphamide
    Urban Emmenegger, Giulio Francia, Annabelle Chow, Yuval Shaked, Andrew Kouri, Shan Man, Robert S. Kerbel · 2011 · Neoplasia
73. Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks
    Bhagelu R. Achyut, Adarsh Shankar, Asm Iskander, Roxan Ara, Kartik Angara, Peng Zeng, Robert A. Knight, Alfonso Guillermo Scicli, Ali S. Arbab · 2015 · Cancer Letters
74. Methods of overcoming treatment resistance in colorectal cancer
    Sally Naji Temraz, Deborah Mukherji, Raafat S. Alameddine, Ali I. Shamseddine · 2013 · Critical Reviews in Oncology/Hematology
75. Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives
    Ying‐Chun Shen, Chiun Hsu, Ann‐Lii Cheng · 2010 · Journal of Gastroenterology
76. Glioblastoma vasculogenic mimicry: signaling pathways progression and potential anti-angiogenesis targets
    Jinming Mao, Jing Liu, Geng Guo, Xinggang Mao, Changxin Li · 2015 · Biomarker Research
77. L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways
    Feng Gao, Sergio X. Vasquez, Feng Su, Svetlana Roberts, Neha Shah, Victor R. Grijalva, Satoshi Imaizumi, Arnab Chattopadhyay, Ekambaram Ganapathy, David Meriwether et al. · 2011 · Integrative Biology
78. Brain angiogenesis in developmental and pathological processes: mechanism and therapeutic intervention in brain tumors
    Woo‐Young Kim, Ho‐Young Lee · 2009 · FEBS Journal
79. Valproic Acid Inhibits Angiogenesis In Vitro and Glioma Angiogenesis In Vivo in the Brain
    Satoru Osuka, Shingo Takano, Shinya Watanabe, Eiichi Ishikawa, Tetsuya Yamamoto, Akira Matsumura · 2012 · Neurologia medico-chirurgica
80. Current status and future directions of anti-angiogenic therapy for gliomas
    Wolfgang Wick, Michael Platten, Antje Wick, Anne Hertenstein, Alexander Radbruch, Martin Bendszus, Frank Winkler · 2015 · Neuro-Oncology
81. Regulation of Vegf signaling by natural and synthetic ligands
    Andrea Rossi, Sébastien Gauvrit, Michele Marass, Luyuan Pan, Cecilia B. Moens, Didier Y. R. Stainier · 2016 · Blood
82. VEGF as a modulator of the innate immune response in glioblastoma
    Kati Turkowski, Susan Brandenburg, Annett Mueller, Irina Kremenetskaia, Alexander D. Bungert, Anne Blank, Matthäus Felsenstein, Peter Vajkoczy · 2017 · Glia
83. MicroRNA‐135a‐3p regulates angiogenesis and tissue repair by targeting p38 signaling in endothelial cells
    Basak Icli, Winona W. Wu, Denizhan Ozdemir, Hao Li, Stefan Haemmig, Xin Liu, Giorgio Giatsidis, Henry S. Cheng, Seyma Nazli Avci, Mervé Kurt et al. · 2019 · The FASEB Journal
84. Angiogenesis and Metabolism: Entwined for Therapy Resistance
    Jiménez-Valerio, Gabriela, Casanovas, Oriol · 2017 · Trends in cancer
85. Essential Role for Endocytosis in the Growth Factor-stimulated Activation of ERK1/2 in Endothelial Cells
    Morgane Gourlaouen, Jonathan C. Welti, Naveen S. Vasudev, Andrew R. Reynolds · 2013 · Journal of Biological Chemistry
86. Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
    Susanna Varkey Ulahannan, Julie Renee Brahmer · 2011 · Cancer Investigation
87. Chronic Inflammation and Colorectal Cancer: The Role of Vascular Endothelial Growth Factor
    Tao Hu, Long Li, Jing Shen, Lin Zhang, Chi Cho · 2015 · Current Pharmaceutical Design
88. CXCR2-Expressing Tumor Cells Drive Vascular Mimicry in Antiangiogenic Therapy–Resistant Glioblastoma
    Kartik Angara, Thaiz F. Borin, Mohammad H. Rashid, Iryna Lebedyeva, Roxan Ara, Ping‐Chang Lin, Asm Iskander, Roni J. Bollag, Bhagelu R. Achyut, Ali S. Arbab · 2018 · Neoplasia
89. Peptides Derived from Type IV Collagen, CXC Chemokines, and Thrombospondin-1 Domain-Containing Proteins Inhibit Neovascularization and Suppress Tumor Growth in MDA-MB-231 Breast Cancer Xenografts
    Jacob E. Koskimaki, Emmanouil D. Karagiannis, Elena Roşca, Farhad Vesuna, Paul T. Winnard, Venu Raman, Zaver M. Bhujwalla, Aleksander S. Popel · 2009 · Neoplasia
90. Recombinant Human VEGF 165 b Inhibits Experimental Choroidal Neovascularization
    Jing Hua, Christine K. Spee, Satoru Kase, Emma Rennel, Anette Magnussen, Yan Qiu, Alexander H. R. Varey, Sandeep Dhayade, A Churchill, Steven J. Harper et al. · 2010 · Investigative Ophthalmology & Visual Science
91. Predictive biomarkers in renal cell cancer: Insights in drug resistance mechanisms
    Johannes Cornelis van der Mijn, James Walter Mier, Henk J. Broxterman, Henk M.W. Verheul · 2014 · Drug Resistance Updates
92. Drug resistance associated with antiangiogenesis therapy
    Hans Petter Eikesdal, Raghu Kalluri · 2009 · Seminars in Cancer Biology
93. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas
    Marc Charles Chamberlain · 2010 · Cancer
94. Antiangiogenesis therapy: an update after the first decade
    Sandro De Falco · 2014 · The Korean Journal of Internal Medicine
95. The emergence of melatonin in oncology: Focus on colorectal cancer
    Emilio Gil‐Martín, Javier Egea, Russel Joseph Reiter, Alejandro Romero · 2019 · Medicinal Research Reviews
96. Carbonic anhydrase 2 (CAII) supports tumor blood endothelial cell survival under lactic acidosis in the tumor microenvironment
    Dorcas A. Annan, Nako Maishi, Tomoyoshi Soga, Randa Dawood, Cong Li, Hiroshi Kikuchi, T. Hojo, Masahiro Morimoto, Tetsuya Kitamura, Mohammad Towfik Alam et al. · 2019 · Cell Communication and Signaling
97. Angiocrine endothelium: from physiology to cancer
    Jennifer Pasquier, Pegah Ghiabi, Lotfi Chouchane, Kaïs Razzouk, Shahin Rafii, Arash Rafii · 2020 · Journal of Translational Medicine
98. Relapse of pathological angiogenesis: functional role of the basement membrane and potential treatment strategies
    Anthony Mukwaya, Lasse D. Jensen, Neil Lagali · 2021 · Experimental & Molecular Medicine
99. Role of bFGF in Acquired Resistance upon Anti-VEGF Therapy in Cancer
    Fatema Tuz Zahra, Md Sanaullah Sajib, Constantinos Marios Mikelis · 2021 · Cancers
100. Inhibition of aquaporin-1 dependent angiogenesis impairs tumour growth in a mouse model of melanoma
     Grazia Paola Nicchia, Cinzia Stigliano, Angelo Sparaneo, Andrea Rossi, Antonio Frigeri, Maria Svelto · 2012 · Journal of Molecular Medicine